Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
793 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Renal Cell Carcinoma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Renal Cell Carcinoma - Pipeline Review, H2 2016, provides an overview of the Renal Cell Carcinoma (Oncology) pipeline landscape. Renal cell carcinoma (RCC, formerly known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule. Symptoms include hematuria, loin pain, abdominal mass, malaise, which is a general feeling of feeling unwell, weight loss and/or loss of appetite, anemia resulting from depression of erythropoietin and erythrocytosis. The predisposing factors are age and hereditary factors. The disease is controlled by chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Renal Cell Carcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Renal Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Renal Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Renal Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 13, 46, 42, 3, 34, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 5, 3 and 4 molecules, respectively.Renal Cell Carcinoma. Renal Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Renal Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Renal Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Renal Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Renal Cell Carcinoma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Renal Cell Carcinoma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Renal Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 7 Renal Cell Carcinoma Overview 8 Therapeutics Development 9 Renal Cell Carcinoma - Therapeutics under Development by Companies 11 Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 18 Renal Cell Carcinoma - Pipeline Products Glance 19 Renal Cell Carcinoma - Products under Development by Companies 23 Renal Cell Carcinoma - Products under Investigation by Universities/Institutes 34 Renal Cell Carcinoma - Companies Involved in Therapeutics Development 35 Renal Cell Carcinoma - Therapeutics Assessment 130 Drug Profiles 162 Renal Cell Carcinoma - Dormant Projects 738 Renal Cell Carcinoma - Discontinued Products 753 Renal Cell Carcinoma - Product Development Milestones 757 Appendix 775
List of Tables
Number of Products under Development for Renal Cell Carcinoma, H2 2016 26 Number of Products under Development for Renal Cell Carcinoma - Comparative Analysis, H2 2016 27 Number of Products under Development by Companies, H2 2016 28 Number of Products under Development by Companies, H2 2016 (Contd..1) 29 Number of Products under Development by Companies, H2 2016 (Contd..2) 30 Number of Products under Development by Companies, H2 2016 (Contd..3) 31 Number of Products under Development by Companies, H2 2016 (Contd..4) 32 Number of Products under Development by Companies, H2 2016 (Contd..5) 33 Number of Products under Development by Companies, H2 2016 (Contd..6) 34 Number of Products under Investigation by Universities/Institutes, H2 2016 35 Comparative Analysis by Late Stage Development, H2 2016 36 Comparative Analysis by Clinical Stage Development, H2 2016 37 Comparative Analysis by Early Stage Development, H2 2016 38 Comparative Analysis by Unknown Stage Development, H2 2016 39 Products under Development by Companies, H2 2016 40 Products under Development by Companies, H2 2016 (Contd..1) 41 Products under Development by Companies, H2 2016 (Contd..2) 42 Products under Development by Companies, H2 2016 (Contd..3) 43 Products under Development by Companies, H2 2016 (Contd..4) 44 Products under Development by Companies, H2 2016 (Contd..5) 45 Products under Development by Companies, H2 2016 (Contd..6) 46 Products under Development by Companies, H2 2016 (Contd..7) 47 Products under Development by Companies, H2 2016 (Contd..8) 48 Products under Development by Companies, H2 2016 (Contd..9) 49 Products under Development by Companies, H2 2016 (Contd..10) 50 Products under Investigation by Universities/Institutes, H2 2016 51 Renal Cell Carcinoma - Pipeline by AbbVie Inc, H2 2016 52 Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2016 53 Renal Cell Carcinoma - Pipeline by Advenchen Laboratories, LLC, H2 2016 54 Renal Cell Carcinoma - Pipeline by Altor BioScience Corporation, H2 2016 55 Renal Cell Carcinoma - Pipeline by Ambrx, Inc., H2 2016 56 Renal Cell Carcinoma - Pipeline by Amgen Inc., H2 2016 57 Renal Cell Carcinoma - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 58 Renal Cell Carcinoma - Pipeline by Apac Biotech Pvt Ltd, H2 2016 59 Renal Cell Carcinoma - Pipeline by arGEN-X BV, H2 2016 60 Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H2 2016 61 Renal Cell Carcinoma - Pipeline by ARMO Biosciences, Inc., H2 2016 62 Renal Cell Carcinoma - Pipeline by Arrowhead Pharmaceuticals, Inc., H2 2016 63 Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H2 2016 64 Renal Cell Carcinoma - Pipeline by Bayer AG, H2 2016 65 Renal Cell Carcinoma - Pipeline by Bio-Cancer Treatment International Limited, H2 2016 66 Renal Cell Carcinoma - Pipeline by BIOCAD, H2 2016 67 Renal Cell Carcinoma - Pipeline by Bionomics Limited, H2 2016 68 Renal Cell Carcinoma - Pipeline by Bionovis SA, H2 2016 69 Renal Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 70 Renal Cell Carcinoma - Pipeline by Boston Biomedical, Inc., H2 2016 71 Renal Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 72 Renal Cell Carcinoma - Pipeline by Calithera Biosciences, Inc., H2 2016 73 Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2016 74 Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2016 75 Renal Cell Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H2 2016 76 Renal Cell Carcinoma - Pipeline by Cytune Pharma SAS, H2 2016 77 Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016 78 Renal Cell Carcinoma - Pipeline by EirGenix Inc., H2 2016 79 Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2016 80 Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2016 81 Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H2 2016 82 Renal Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 83 Renal Cell Carcinoma - Pipeline by Five Prime Therapeutics Inc, H2 2016 84 Renal Cell Carcinoma - Pipeline by Gene Techno Science Co., Ltd., H2 2016 85 Renal Cell Carcinoma - Pipeline by Genor BioPharma Co Ltd, H2 2016 86 Renal Cell Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2016 87 Renal Cell Carcinoma - Pipeline by Hemispherx Biopharma, Inc., H2 2016 88 Renal Cell Carcinoma - Pipeline by Horizon Pharma Plc, H2 2016 89 Renal Cell Carcinoma - Pipeline by Hutchison MediPharma Limited, H2 2016 90 Renal Cell Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H2 2016 91 Renal Cell Carcinoma - Pipeline by Immune Design Corp., H2 2016 92 Renal Cell Carcinoma - Pipeline by Immunicum AB, H2 2016 93 Renal Cell Carcinoma - Pipeline by ImmunoGen, Inc., H2 2016 94 Renal Cell Carcinoma - Pipeline by Immunomedics, Inc., H2 2016 95 Renal Cell Carcinoma - Pipeline by Incuron, LLC, H2 2016 96 Renal Cell Carcinoma - Pipeline by Incyte Corporation, H2 2016 97 Renal Cell Carcinoma - Pipeline by Inspyr Therapeutics Inc, H2 2016 98 Renal Cell Carcinoma - Pipeline by Johnson & Johnson, H2 2016 99 Renal Cell Carcinoma - Pipeline by KAHR medical Ltd., H2 2016 100 Renal Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 101 Renal Cell Carcinoma - Pipeline by KineMed, Inc., H2 2016 102 Renal Cell Carcinoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 103 Renal Cell Carcinoma - Pipeline by Lead Discovery Center GmbH, H2 2016 104 Renal Cell Carcinoma - Pipeline by Mabion SA, H2 2016 105 Renal Cell Carcinoma - Pipeline by MacroGenics, Inc., H2 2016 106 Renal Cell Carcinoma - Pipeline by MedImmune LLC, H2 2016 107 Renal Cell Carcinoma - Pipeline by Medivation, Inc., H2 2016 108 Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2016 109 Renal Cell Carcinoma - Pipeline by Merck KGaA, H2 2016 110 Renal Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 111 Renal Cell Carcinoma - Pipeline by Molecular Partners AG, H2 2016 112 Renal Cell Carcinoma - Pipeline by Mologen AG, H2 2016 113 Renal Cell Carcinoma - Pipeline by Monopar Therapeutics LLC, H2 2016 114 Renal Cell Carcinoma - Pipeline by Mycenax Biotech Inc., H2 2016 115 Renal Cell Carcinoma - Pipeline by Nektar Therapeutics, H2 2016 116 Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H2 2016 117 Renal Cell Carcinoma - Pipeline by Novartis AG, H2 2016 118 Renal Cell Carcinoma - Pipeline by NovaTarg Therapeutics, Inc, H2 2016 119 Renal Cell Carcinoma - Pipeline by Omeros Corporation, H2 2016 120 Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2016 121 Renal Cell Carcinoma - Pipeline by OncoMax, H2 2016 122 Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 123 Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H2 2016 124 Renal Cell Carcinoma - Pipeline by Pfizer Inc., H2 2016 125 Renal Cell Carcinoma - Pipeline by Pharmacyclics Inc, H2 2016 126 Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H2 2016 127 Renal Cell Carcinoma - Pipeline by PsiOxus Therapeutics Limited, H2 2016 128 Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016 129 Renal Cell Carcinoma - Pipeline by Richter Gedeon Nyrt., H2 2016 130 Renal Cell Carcinoma - Pipeline by Sevion Therapeutics, Inc., H2 2016 131 Renal Cell Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2016 132 Renal Cell Carcinoma - Pipeline by Sorrento Therapeutics Inc, H2 2016 133 Renal Cell Carcinoma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 134 Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals Inc, H2 2016 135 Renal Cell Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 136 Renal Cell Carcinoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 137 Renal Cell Carcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 138 Renal Cell Carcinoma - Pipeline by TC BioPharm Limited, H2 2016 139 Renal Cell Carcinoma - Pipeline by Theravectys SA, H2 2016 140 Renal Cell Carcinoma - Pipeline by Tocagen Inc., H2 2016 141 Renal Cell Carcinoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 142 Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H2 2016 143 Renal Cell Carcinoma - Pipeline by Tyrogenex, Inc., H2 2016 144 Renal Cell Carcinoma - Pipeline by Vascular Biogenics Ltd., H2 2016 145 Renal Cell Carcinoma - Pipeline by X4 Pharmaceuticals, Inc., H2 2016 146 Assessment by Monotherapy Products, H2 2016 147 Assessment by Combination Products, H2 2016 148 Number of Products by Stage and Target, H2 2016 150 Number of Products by Stage and Mechanism of Action, H2 2016 163 Number of Products by Stage and Route of Administration, H2 2016 176 Number of Products by Stage and Molecule Type, H2 2016 178 Renal Cell Carcinoma - Dormant Projects, H2 2016 754 Renal Cell Carcinoma - Dormant Projects (Contd..1), H2 2016 755 Renal Cell Carcinoma - Dormant Projects (Contd..2), H2 2016 756 Renal Cell Carcinoma - Dormant Projects (Contd..3), H2 2016 757 Renal Cell Carcinoma - Dormant Projects (Contd..4), H2 2016 758 Renal Cell Carcinoma - Dormant Projects (Contd..5), H2 2016 759 Renal Cell Carcinoma - Dormant Projects (Contd..6), H2 2016 760 Renal Cell Carcinoma - Dormant Projects (Contd..7), H2 2016 761 Renal Cell Carcinoma - Dormant Projects (Contd..8), H2 2016 762 Renal Cell Carcinoma - Dormant Projects (Contd..9), H2 2016 763 Renal Cell Carcinoma - Dormant Projects (Contd..10), H2 2016 764 Renal Cell Carcinoma - Dormant Projects (Contd..11), H2 2016 765 Renal Cell Carcinoma - Dormant Projects (Contd..12), H2 2016 766 Renal Cell Carcinoma - Dormant Projects (Contd..13), H2 2016 767 Renal Cell Carcinoma - Dormant Projects (Contd..14), H2 2016 768 Renal Cell Carcinoma - Discontinued Products, H2 2016 769 Renal Cell Carcinoma - Discontinued Products (Contd..1), H2 2016 770 Renal Cell Carcinoma - Discontinued Products (Contd..2), H2 2016 771 Renal Cell Carcinoma - Discontinued Products (Contd..3), H2 2016 772
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
